NASDAQ: CAMPCamp4 Therapeutics Corp Stock
$1.77+0.02 (+1.14%)
Updated Apr 30, 2025
CAMP Price
$1.77
Fair Value Price
N/A
Market Cap
$35.69M
52 Week Low
$1.61
52 Week High
$12.30
P/E
-0.16x
P/B
0.57x
P/S
37.55x
PEG
N/A
Dividend Yield
N/A
Revenue
$652.00k
Earnings
-$51.79M
Gross Margin
100%
Operating Margin
-7,943.4%
Profit Margin
-7,943.4%
Debt to Equity
0.24
Operating Cash Flow
-$46M
Beta
1.28
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CAMP Overview
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CAMP's potential to beat the market
- CAMP doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CAMP
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important CAMP news, forecast changes, insider trades & much more!
CAMP News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CAMP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CAMP is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CAMP is good value based on its book value relative to its share price (0.57x), compared to the US Biotechnology industry average (4.45x)
P/B vs Industry Valuation
CAMP is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CAMP due diligence checks available for Premium users.
Valuation
CAMP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.16x
Industry
-162.28x
Market
29.18x
CAMP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.57x
Industry
4.45x
CAMP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CAMP's financial health
Profit margin
Revenue
$652.0k
Net Income
-$13.3M
Profit Margin
-2,036.7%
CAMP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CAMP's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$78.3M
Liabilities
$15.2M
Debt to equity
0.24
CAMP's short-term assets ($66.38M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CAMP's short-term assets ($66.38M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CAMP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.3M
Investing
-$263.0k
Financing
$73.2M
CAMP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CAMP vs Biotech Stocks
Camp4 Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.